For its first fiscal quarter (ending March 31), Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has reported a -217% decline in E.P.S. from $0.06 a year ago to $-0.07 in the current quarter. For the latest four quarters through March 31, E.P.S. were $-0.08 compared to $0.29 a year ago — a decline of -128%.
Recent Price Action
Vanda Pharmaceuticals Inc (NASDAQ: VNDA) stock closed at $5.36 on 5/8/24 after a decline of -2.2%. However, trading volume in this decline was below average at 72% of normal. The stock has been weak relative to the market over the last nine months but has risen 12.6% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, VNDA is expected to be Value Creation neutral.
Vanda Pharmaceuticals has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing contradictory signals. Vanda Pharmaceuticals has a slightly positive Appreciation Score of 69 but a slightly negative Power Rating of 31, leading to the Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment